Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14185041 | 1.00 | SRD5A2 (0.37) | SRD5A2SRD5A1PSEN1PSEN2APH1B | |
| SCHEMBL14185035 | 0.87 | SRD5A2 (0.40) | SRD5A2SRD5A1AR | |
| SCHEMBL14214528 | 0.81 | SRD5A2 (0.37) | SRD5A2SRD5A1AR | |
| SCHEMBL13603625 | 0.77 | SRD5A2 (0.49) | SRD5A2SRD5A1AR | |
| SCHEMBL13611185 | 0.77 | SRD5A2 (0.49) | SRD5A2SRD5A1AR | |
| SCHEMBL13603644 | 0.76 | SRD5A2 (0.50) | SRD5A2SRD5A1AR | |
| SCHEMBL13611190 | 0.76 | SRD5A2 (0.50) | SRD5A2SRD5A1AR | |
| SCHEMBL14185040 | 0.75 | ALDH1A1 (0.41) | SRD5A2SRD5A1AR | |
| SCHEMBL14214530 | 0.75 | ALDH1A1 (0.41) | SRD5A2SRD5A1AR | |
| SCHEMBL14185021 | 0.73 | PSEN1 (0.40) | SRD5A2SRD5A1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | AR, CYP17A1, SHBG | SRD5A2 20/4885SRD5A1 18/4885PSEN1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.